Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Sep 02, 2022 4:50pm
209 Views
Post# 34939261

Welcome AllinATE ...

Welcome AllinATE ...I usually take the time to welcome new names.
This time I was too busy thinking something else - so - once again I appologize.

Want to take this time to give you an appropriate "Welcome !"

-------------------------

Let's see what next week brings us ... sure hoping we get a kick-off for Phase 2 Molar Extraction, the sooner the better.

-------------------------

It looks like we had (maybe) one trade of 5,000 shares register today on the TSX.
I picked up 1,000 but it did not register - as very few of my BMO purchases ever register.
Then we had 300 bought on the US-OTC (if that was even today).

Hopijng we can get a lot more interest going after Phase 2 begins.

-------------------------

Here's another interesting article that I think plays very well to the physiology of the human body.
Saw it yesterday - it's on ultraprocessed foods.  I think it comes full circle regarding a previous article I shared on red meat.

Our body's ability to produce the required H2S (at the cell level) becomes a growing problem as we age.  Throw in a bad diet with the likes of ultraprocessed foods and we're likely aging our cells faster than ever.

ATB-340 for cell health will likely be a real counter-move to our diets and to our lifestyles in the 21st century.

In the past I called 340 a potential daily vitamin to slow the aging process.

Today, I say it differently.  Protein sulfhydration decreases as we age.  Extraction of H2S from proteins becomes less effective.  Synthesis of H2S via trans-sulfiration becomes less effective.

Therefore - just maybe - we're onto the counter attack to our crazy lifestyles in th e21 century !!!!


https://www.cnn.com/2022/09/01/health/ultraprocessed-foods-cancer-early-death-wellness/index.html

<< Previous
Bullboard Posts
Next >>